| Title |
Opportunity Number |
Funding Agency |
Deadline |
|
Toxic Exposures Research Program (TERP)
|
HT942524TERP |
USAMRAA |
Pre-Application: August 13, 2024; Application: November 7, 2024 |
|
Alcohol and Substance Use Disorders Research Program (ASUDRP)
|
HT942524ASUDRP |
USAMRAA |
LOI: September 10, 2024; Application: September 24, 2024 |
|
NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
|
PAR-23-027 |
NIH/NINDS/NIAID |
LOI: 30 days before application due date; October 17, 2024; October 17, 2025; October 16, 2026 |
|
Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
|
RFA-AI-24-029 |
NIH/NIAID |
LOI: 30 days prior to due date October 09, 2024 |
|
Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)
|
RFA-DA-25-044 |
NIH |
LOI: September 29, 2024; Submission: October 29,2024 |
|
Engineering of Biomedical Systems
|
PD-23-5345 |
U.S. National Science Foundation (NSF) |
Throughout the year 2024 |
|
Biosensing
|
PD-20-7909 |
U.S. National Science Foundation (NSF) |
Throughout the year 2024 |
|
Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed)
|
NOT-AI-23-073 |
NIAID/NIH |
Forecasted |
|
Breast Cancer Research Program (BCRP)
|
HT942524BCRP |
USAMRAA |
Varies with award |
|
Neurofibromatosis Research Program (NFRP)
|
HT942524NFRPNFRALA |
USAMRAA |
LOI: August 22, 2024; Application: September 12, 2024; Oral Presentation: January 2025 |
|
Bone Marrow Failure Research Program (BMFRP)
|
HT942524BMFRP |
USAMRAA |
Pre-Application: July 17, 2024; Application: October 9, 2024 |
|
NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
|
PAR-22-225 |
NIH, NIAID |
Non-AIDS Related Due Dates – June 11, 2024; January 10, 2025 | AIDS Related Due Dates - September 7, 2024; May 7, 2025 |
|
Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA)
|
HDTRA1-24-S-0002 |
Defense Threat Reduction Agency (DTRA CTR) |
April 28, 2029 |
|
Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
|
PAR-21-167 |
NIH |
June 16, 2024; October 16, 2024 |
|
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional
|
RFA-CA-24-006 |
NIH |
LOI: 30 days prior to closing date; Closing Date: December 04, 2024 |
|
NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional)
|
RFA-EY-24-003 |
NIH |
LOI July 12, 2024; Final August 13, 2024 |
|
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
|
RFA-NS-22-034 |
NIH |
10/02/2024 |
|
Combat Readiness—Medical Research Program
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Lupus Research Program (LRP)
|
HT942524LRP |
DOD-AMRAA |
Pre-App due: July 17, 2024; Application due: August 6, 2024 |
|
Parkinson’s Research Program (PRP)
|
HT942524PRP |
DOD-AMRAA |
Varies with award |
|
Vision Research Program (VRP)
|
HT942524VRP |
DOD-AMRAA |
Pre-Application (July 11, 2024); Application (November 8, 2024) |
|
Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)
|
HT942524TBIPHRP |
DOD-AMRAA |
Varies with award |
|
Military Health System Research Program (MHSRP)
|
HT9425-25-MHSRP |
DOD-AMRAA |
LOI Submission: 05/28/2024; Application: 06 Sep 24 |
|
Prostate Cancer Research Program (PCRP)
|
HT942524PCRP |
DOD-AMRAA |
Varies with award |
|
Peer Reviewed Orthopaedic Research Program (PRORP)
|
HT942524PRORP |
DOD-AMRAA |
Varies with award |
|
Melanoma Research Program (MRP)
|
HT942524MRP |
DOD-AMRAA |
Pre-Application (LOI): 07/29/2024; Full-Application: 08/26/2024 |
|
Duchenne Muscular Dystrophy Research Program (DMDRP)
|
HT942524DMDRP |
DOD-AMRAA |
Pre-Application (LOI): 08/01/2024; Full-Application: 08/22/2024 |
|
Peer Reviewed Cancer Research Program (PRCRP)
|
HT942524PRCRP |
DOD-AMRAA |
Varies with award |
|
AMSSM CRN Request For Proposals
|
RFP |
AMSSM |
LOI: 07/12/2024, Full Application: 10/11/2024 |
|
ARPA-H Health Science Futures Office Innovative Solutions Opening (ISO)
|
ARPA-H-SOL-24-104 |
ARPA-H |
3/15/2025 |
|
ARPA-H Resilient Systems Office Office-wide Innovative Solutions Opening (ISO)
|
ARPA-H-SOL-24-103 |
ARPA-H |
3/15/2025 |
|
Prostate Cancer Research Program (PCRP)
|
HT942524PCRP |
DOD-AMRAA |
Varies with award |
|
Pancreatic Cancer Research Program (PCARP)
|
HT9425-24-PCARP |
DOD-AMRAA |
Varies with award |
|
Autism Research Program (ARP)
|
HT942524ARP |
DOD-AMRAA |
Varies with award |
|
Tuberous Sclerosis Complex Research Program (TSCRP)
|
HT942524TSCRP |
DOD-AMRAA |
Pre-app due Jun 12, 2024; App due Aug 1, 2024 |
|
Tick-Borne Disease Research Program (TBDRP)
|
HT942524TBDRP |
DOD-AMRAA |
Pre-app due Jun 26, 2024; App due Oct 3, 2024 |
|
Multiple Sclerosis Research Program (MSRP)
|
HT942524MSRP |
DOD-AMRAA |
Varies with award |
|
Military Burn Research Program (MBRP)
|
HT942524MBRP |
DOD-AMRAA |
Pre-app due Jun 3, 2024; App due Sep 9, 2024 |
|
Rare Cancers Research Program (RCRP)
|
HT942524RCRP |
DOD-AMRAA |
Varies with award |
|
Alcohol and Substance Use Disorders Research Program (ASUDRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Ovarian Cancer Research Program (OCRP)
|
HT942524OCRP |
DOD-AMRAA |
Varies with award |
|
Joint Warfighter Medical Research Program (JWMRP)
|
HT942524SJWMRPMMRDA |
DOD-AMRAA |
Pre-app due June3, 2024; App due Aug 29, 2024 |
|
Kidney Cancer Research Program (KCRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Reconstructive Transplant Research Program (RTRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Spinal Cord Injury Research Program (SCIRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Hearing Restoration Research Program (HRRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Lung Cancer Research Program (LCRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Amyotrophic Lateral Sclerosis Research Program (ALSRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Peer Reviewed Alzheimer's Research Program (PRARP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
U.S. Army Research Institute for the Behavioral and Social Sciences BAA for Basic Research (FY2025)
|
W911NF24S0005 |
DOD-AMC |
7/1/2024 |
|
Epilepsy Research Program (ERP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
|
RFA-NS-24-019 |
NIH |
1/8/2027 |
|
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
|
PAR-24-036 |
NIH |
11/3/2026 |
|
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
|
PAR-24-035 |
NIH |
11/3/2026 |
|
Notice of Special Interest (NOSI): Chronic Inflammation of the Oral Cavity - An Agent for Oral Mucosal Disease
|
NOT-DE-23-007 |
NIH |
5/10/2027 |
|
Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives
|
NOT-AI-23-076 |
NIH |
7/17/2026 |
|
Broad Agency Announcement (BAA) for the Protection of Deployed Military Personnel From Threats Posed by Arthropod Disease Vectors
|
AFPMB-BAA-24-01 |
DoD |
10/19/2028 |
|
2024 Human Exploration Research Opportunities (HERO) Overview
|
80JSC024NA001 |
NASA Johnson Space Center |
10/30/2024 |
|
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
|
BAA-23-100-SOL-00004 |
HHS/BARDA-ASPR |
10/10/2028 |
|
BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
|
RFA-EY-23-001 |
NIH |
6/16/2026 |
|
US Special Operations Command - Broad Agency Announcement for Extramural Biomedical Research and Development
|
HT9425-23-S-SOC1 |
DOD-AMRAA |
7/31/2028 |
|
United States Army Research Institute for the Behavioral And Social Sciences (ARI) BAA for Basic, Applied, And Advanced Scientific Research
|
W911NF-23-S-0010 |
DOD-AMC |
4/30/2028 |
|
Orthopaedic Research and Education Foundation (OREF)
|
various |
OREF |
varies with award |
|
AHRQ Announces Interest in Healthcare Associated Infections and Combating Antibiotic Resistant Bacteria Research
|
NOT-HS-23-003 |
AHRQ |
See Notice |
|
Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)
|
NOT-AI-23-013 |
NIH |
Expires January 08, 2026 |
|
Large Research Projects for Prevention of Healthcare-Associated Infections (R01)
|
PA-21-265 |
NIH |
expires May 27, 2025 |
|
Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
|
PA-22-047 |
NIH |
expires October 31, 2026 |
|
Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)
|
PA-22-048 |
NIH |
expires October 31, 2026 |
|
Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)
|
PA-21-164 |
NIH |
expires July 18, 2024 |
|
Notice of Special Interest (NOSI): Complement in Fundamental Immunology
|
NOT-AI-23-012 |
NIH |
expires January 08, 2026 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
|
PAR-22-243 |
NIH |
expires September 08, 2025 |
|
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
|
PAR-23-047 |
NIH |
1/8/2026 |
|
Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission
|
NOT-AI-22-064 |
NIH |
1/8/2026 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
|
PAR-22-242 |
NIH |
9/8/2025 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
|
PAR-22-243 |
NIH |
9/8/2025 |
|
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early Stage Development (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-209 |
NIH (NINDS, NEI, NIDA, NIEHS) |
10/18/2024 |
|
DoD USAMRDC FY23-FY27 Broad Agency Announcement for Extramural Medical Research
|
HT9425-23-S-BAA1 |
DOD-AMRAA |
9/30/2027 |
|
Broad Agency Announcement Research and Development In Support of The Joint Program Executive Office For Chemical, Biological, Radiological And Nuclear Defense (JPEO-CBRND), JPM MEDICAL AND JPL EB
|
W911SR-22-R-CBRN |
DOD |
6/26/2027 |
|
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-209 |
NIH |
10/18/2024 |
|
Airman Readiness Medical Research (ARMR) Hybrid BAA
|
FA8650-20-S-6008 |
DoD-AFRL |
5/1/2025 |
|
Research Interests of the Air Force Office of Scientific Research
|
FA9550-21-S-0001 |
DOD-AFOSR |
|
|
US Army Combat Capabilities Development Command Broad Agency Announcement
|
W911QY-20-R-0022 |
DOD-AMC-ACCAPGN |
2/28/2025 |
|
BARDA DRIVe EZ-BAA
|
BAA-20-100-SOL-0002 |
HHS - BARDA |
7/6/2024 |
|
Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine
|
NOT-AI-22-013 |
NIH (NIAID) |
1/8/2025 |
|
Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery
|
NOT-AI-22-014 |
NIH (NIAID) |
1/8/2025 |
|
Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
|
PAR-22-127 |
NIH (NIGMS, NIA, NCI) |
5/8/2025 |
|
Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
|
PAR-22-126 |
NIH (NIGMS, NIA, NCI) |
5/8/2025 |
|
Research Program Award (R35 Clinical Trial Optional)
|
RFA-NS-22-038 |
NIH (NINDS) |
7/16/2024 |
|
Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-076 |
NIH (NINDS) |
5/8/2025 |
|
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
|
NOT-HL-20-814 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
|
RFA-HL-23-010 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
|
RFA-HL-23-013 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
|
RFA-HL-23-014 |
NIH (NHLBI) |
12/22/2024 |
|
RFI: Neurotrauma Diagnosis, Monitoring, and Assessment State of Technology Meeting
|
MTEC-23-11-Neurotrauma |
MTEC |
9/14/2023 |
